My Treatment Approach: Androgen Receptor Inhibitors and the Evolving Treatment Paradigm in Castration-Sensitive Prostate Cancer - Episode 4

The EMBARK trial investigating enzalutamide in NM CSPC

,

Prostate cancer experts analyze the EMBARK trial, emphasizing the potential impact of an androgen receptor inhibitor in the treatment of non-metastatic castration-sensitive prostate cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer
    EP. 2: Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer
    EP. 3: Evolving Treatment Paradigm and NCCN Guideline Updates
    Now Viewing
    EP. 4: The EMBARK trial investigating enzalutamide in NM CSPC
    EP. 5: The Role of PSA Doubling Time in Risk Assessment
    EP. 6: Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA
    EP. 7: Patient Case 2: Metastatic CSPC
    EP. 8: Final Thoughts on CSPC
    1. Dr. Efstathiou asks Dr. Freedland: Enzalutamide is currently the only androgen receptor inhibitor approved for non-metastatic CSPC. Can you summarize the key data from the EMBARK trial supporting its use in this setting?
      1. Please comment of the high risk study population evaluated in the EMBARK trial
      2. What were the primary endpoints and efficacy findings from the EMBARK trial? Please also comment on your impressions of the monotherapy arm.
      3. What are your impressions of the safety data from EMBARK?
    x